Actual Treatment Options for Giant Cell Arteritis

Moosig F, Schmalzing M, Aries PM, Henes J, Lamprecht P, Rech J, Witte T (2019)

Publication Type: Journal article

Publication year: 2019

Journal

Deutsche Medizinische Wochenschrift Georg Thieme Verlag

Book Volume: 144

Pages Range: 595-600

Journal Issue: 9

DOI: 10.1055/a-0832-3563

Abstract

To prevent serious complications such as permanent loss of vision and structural vascular damage, treatment must be initiated quickly in patients with giant-cell arteritis (GCA). So far, usually long-term corticosteroids in cumulative high dosages have been the standard therapy option. However, steroids are often insufficient to achieve adequate disease control and are associated with serious adverse events. Therefore, steroid-sparing therapy options are the focus of interest.

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

PRI Pediatric Rheumatology Research Institute GmbH DE Germany (DE) Universitätsklinikum Würzburg DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE)

How to cite

APA:

Moosig, F., Schmalzing, M., Aries, P.M., Henes, J., Lamprecht, P., Rech, J., & Witte, T. (2019). Actual Treatment Options for Giant Cell Arteritis. Deutsche Medizinische Wochenschrift, 144(9), 595-600. https://dx.doi.org/10.1055/a-0832-3563

MLA:

Moosig, Frank, et al. "Actual Treatment Options for Giant Cell Arteritis." Deutsche Medizinische Wochenschrift 144.9 (2019): 595-600.

BibTeX: Download